Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Suven Life Sciences Ltd
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 3 | 4 | 3 | 2 | 2 | 1 | 3 | 2 | 1 | 2 | 1 | 3 | 2 |
| Expenses + | 34 | 32 | 27 | 49 | 33 | 32 | 55 | 41 | 45 | 53 | 81 | 106 | 52 |
| Operating Profit | -32 | -28 | -24 | -46 | -30 | -31 | -52 | -39 | -44 | -51 | -80 | -103 | -51 |
| OPM % | -1,208% | -737% | -768% | -1,885% | -1,267% | -3,024% | -2,032% | -2,435% | -2,981% | -2,714% | -8,671% | -3,678% | -3,331% |
| Other Income + | 6 | 6 | 13 | 6 | 4 | 4 | 4 | 2 | 1 | 1 | 4 | 3 | 7 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 2 |
| Profit before tax | -28 | -24 | -13 | -42 | -28 | -28 | -50 | -39 | -44 | -52 | -77 | -102 | -46 |
| Tax % | 0% | 0% | 0% | 0% | -4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit + | -28 | -24 | -13 | -42 | -27 | -28 | -50 | -39 | -44 | -52 | -77 | -102 | -46 |
| EPS in Rs | -1.27 | -1.10 | -0.58 | -1.91 | -1.22 | -1.29 | -2.28 | -1.79 | -2.01 | -2.36 | -3.40 | -4.48 | -1.73 |
Financials of Suven Life Sciences Ltd
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 521 | 499 | 543 | 625 | 286 | 13 | 13 | 12 | 14 | 12 | 7 | 7 |
| Expenses + | 361 | 398 | 414 | 427 | 300 | 128 | 93 | 134 | 139 | 140 | 172 | 292 |
| Operating Profit | 159 | 102 | 129 | 198 | -14 | -116 | -80 | -122 | -126 | -128 | -166 | -284 |
| OPM % | 31% | 20% | 24% | 32% | -5% | -917% | -593% | -1,032% | -929% | -1,094% | -2,487% | -4,001% |
| Other Income + | 9 | 19 | 21 | 23 | 27 | 14 | 8 | 5 | 14 | 29 | 11 | 14 |
| Interest | 5 | 6 | 6 | 5 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Depreciation | 12 | 18 | 21 | 21 | 11 | 4 | 4 | 4 | 7 | 6 | 6 | 6 |
| Profit before tax | 152 | 98 | 123 | 196 | 0 | -106 | -77 | -122 | -118 | -106 | -161 | -276 |
| Tax % | 28% | 26% | 29% | 37% | 15,038% | -11% | -7% | 0% | 0% | -1% | 0% | 0% |
| Net Profit + | 109 | 72 | 87 | 124 | -24 | -94 | -72 | -122 | -118 | -105 | -161 | -276 |
| EPS in Rs | 5.70 | 3.76 | 4.57 | 6.48 | -1.25 | -4.94 | -3.78 | -5.59 | -5.42 | -4.82 | -7.37 | -10.48 |
| Dividend Payout % | 7% | 35% | 15% | 15% | -80% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Suven Life Sciences Ltd
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 15 | 22 | 22 | 22 | 26 |
| Reserves | 547 | 583 | 654 | 755 | 226 | 131 | 95 | 82 | 354 | 248 | 88 | 565 |
| Borrowings + | 109 | 83 | 71 | 34 | 3 | 6 | 5 | 3 | 2 | 1 | 0 | 17 |
| Other Liabilities + | 105 | 74 | 78 | 118 | 62 | 33 | 16 | 9 | 12 | 14 | 25 | 16 |
| Total Liabilities | 773 | 751 | 816 | 919 | 303 | 182 | 128 | 108 | 389 | 285 | 135 | 624 |
| Fixed Assets + | 172 | 305 | 306 | 308 | 22 | 25 | 21 | 38 | 37 | 28 | 60 | 73 |
| CWIP | 107 | 7 | 10 | 25 | 0 | 0 | 5 | 4 | 0 | 0 | 0 | 4 |
| Investments | 0 | 0 | 301 | 279 | 223 | 0 | 0 | 45 | 46 | 76 | 22 | 181 |
| Other Assets + | 494 | 439 | 199 | 308 | 58 | 157 | 103 | 22 | 305 | 181 | 53 | 367 |
| Total Assets | 773 | 751 | 816 | 919 | 303 | 182 | 128 | 108 | 389 | 285 | 135 | 624 |
Financials of Suven Life Sciences Ltd
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 143 | 68 | 109 | 70 | -53 | -135 | -96 | -128 | -116 | -115 | -154 | -302 |
| Cash from Investing Activity + | -110 | -39 | -311 | -1 | 30 | 146 | 56 | -22 | -248 | 94 | 155 | -462 |
| Cash from Financing Activity + | 179 | -68 | -30 | -52 | 5 | 3 | 35 | 146 | 396 | -1 | -1 | 757 |
| Net Cash Flow | 212 | -39 | -232 | 17 | -18 | 14 | -5 | -4 | 32 | -22 | 0 | -7 |
| Free Cash Flow | 25 | 10 | 79 | 28 | -92 | -137 | -102 | -147 | -119 | -113 | -191 | -307 |
| CFO/OP | 113% | 93% | 111% | 57% | 262% | 114% | 119% | 104% | 91% | 95% | 93% | 106% |
Financials of Suven Life Sciences Ltd
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 28 | 39 | 31 | 36 | 3 | 66 | 48 | 40 | 22 | 40 | 73 | 78 |
| Inventory Days | 165 | 183 | 222 | 329 | 0 | |||||||
| Days Payable | 89 | 78 | 91 | 134 | ||||||||
| Cash Conversion Cycle | 105 | 144 | 162 | 231 | 3 | 66 | 48 | 40 | 22 | 40 | 73 | 78 |
| Working Capital Days | 49 | 55 | 42 | 82 | 23 | 704 | 1,084 | 234 | 265 | 101 | -440 | 9,156 |
| ROCE % | 13% | 15% | 24% | -4% | -54% | -58% | -118% | -53% | -36% | -87% | -77% |